Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Eligible age
18–65 yrs
Accepts
All genders
Locations
8 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
CLARITY (Clinical Assessment of Response in the Treatment of Depression with Daytime Sleepiness Using Solriamfetol) is a Phase 3, double-blind, placebo-controlled, multicenter randomized withdrawal trial in patients with major depressive disorder (MDD) with excessive daytime sleepiness (EDS) symptoms consisting of an open-label solriamfetol treatment period and a randomized, double-blind treatment period.
Sponsor: Axsome Therapeutics, Inc.
You may qualify if…
- ✓ Currently meets the DSM-5 criteria for MDD without psychotic features, based on the SCID-5-CT
- ✓ Excessive daytime sleepiness symptoms
- ✓ Able to comply with study procedures
- ✓ Male or female, aged 18 to 65 years inclusive
You may not qualify if…
- ✕ Any clinically significant medical (e.g., OSA, narcolepsy), behavioral, or psychiatric disorder, other than MDD with EDS symptoms
- ✕ Unable to comply with study procedures
- ✕ Medically inappropriate for study participation in the opinion of the investigator
Where it's recruiting
Chino · Redlands · Walnut Creek
Jacksonville · Miami
Cherry Hill · Toms River
Brooklyn · The Bronx
Cincinnati
Portland
Memphis
Dallas
Source: ClinicalTrials.gov · NCT07484217 · last updated 2026-03-20